Our Research Focus
Clonal Hematopoiesis (CH)
We investigate the intricate mechanisms underlying CH, exploring its development, clonal expansion, and progression to myeloid malignancies. We examine the genetic mutations and epigenetic alterations that drive the development and expansion and malignant transformation of clonal hematopoiesis. Our research aims to unravel the genetic and environmental factors that contribute to the evolution of CH into more severe forms of blood cancers, thereby opening new avenues for early intervention and treatment strategies.
Minimal Residual Disease (MRD) Monitoring and Biology
The lab is at the forefront of developing novel approaches for MRD monitoring, with a particular emphasis on the use of cell free DNA (cfDNA). Our work in this area is redefining how MRD is detected and understood, contributing to more accurate assessments of disease status and treatment efficacy.
Germline Predisposition to Myeloid Malignancies and Myeloproliferative Neoplasms
(MPN)
Understanding the genetic underpinnings of myeloid malignancies is a key area of our research. We investigate the role of inherited genetic factors in the development of these diseases. Our studies aim to identify genetic markers that could predict the risk of developing myeloid malignancies and MPN, offering a path toward preventive strategies and personalized medicine.
Mitochondrial Heteroplasmy in Myeloid Malignancies
We study the impact of mitochondrial somatic mutations, also known as heteroplasmy, in the development of myeloid malignancies. We are investigating how these mutations contribute to the onset and progression of Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Additionally, our work aims to explore the potential of mitochondrial mutations as prognostic markers and therapeutic targets in these conditions.